LLY Stock Recent News

September has garnered a reputation as the worst month for stock market performance, supported by compelling historical data.

Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.

Key Points Jim Cramer's Mad Money offers insights valuable to income investors, despite his broader focus on growth.

The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.

The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.

Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.

Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI picks.

Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-loss sector. Eli Lilly's move into the obesity drug market is reshaping the global pharma landscape.

Trading is quiet in Eli Lilly and Co  LLY on Thursday. The stock has stalled out at a resistance level.

Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron's convenience, scalability, and potential dual-indication label position it as a key driver for Eli Lilly's revenue diversification and premium valuation. Despite payer coverage and tolerability challenges, the massive eligible population and orforglipron's advantages should drive exponential sales growth.